Licensing opportunities
At Oncode we actively seek collaboration to further develop technologies which are invented in our lab.
Please find below the list of technologies which we would like to advance together with partners from industry:
- Single Cell Ribosome Profiling (scRibo-seq) [pdf]
- Wnt-agonists to Prevent Intestinal Tumorigenesis [pdf]
- Human stem cell based mutagenesis assay for accurate genotoxicity and MoA evaluation [pdf]
- A novel c DC1 helped gene signature to predict clinical outcome in cancer patients [pdf]
Oncode is responsible for negotiating all options, term sheets, licenses or assignment agreements for technology developed by its investigators. Our team of experienced business developers forms the primary point of contact for investigators and partners from industry. For each technology contact details for the responsible business developers are found in the corresponding non-confidential disclosure.
For general questions, please don't hesitate to send us an email.
Emil Pot
Business Development
Emil Pot
Business Development
With an educational background in law, Emil has gained over 25 years of experience as a patent attorney and business developer. In his capacity as business development manager at the Flemish Institute for Biotechnology (VIB) he drafted and negotiated licensing, R&D and IP agreements and helped creating two start-up companies. He joined ActoGeniX as general counsel and was responsible for all business development, legal and IP matters. The company raised a total of €45MM in three consecutive financing rounds. Emil is a registered patent attorney, does business development for NLO and acts as CEO of Allero Therapeutics.
At Oncode Emil helps to translate fundamental research to the market by developing and executing IP strategies, advising and assisting in company creation and building and maintaining stakeholder relations.
View Bio
Emil Pot
Business Development
With an educational background in law, Emil has gained over 25 years of experience as a patent attorney and business developer. In his capacity as business development manager at the Flemish Institute for Biotechnology (VIB) he drafted and negotiated licensing, R&D and IP agreements and helped creating two start-up companies. He joined ActoGeniX as general counsel and was responsible for all business development, legal and IP matters. The company raised a total of €45MM in three consecutive financing rounds. Emil is a registered patent attorney, does business development for NLO and acts as CEO of Allero Therapeutics.
At Oncode Emil helps to translate fundamental research to the market by developing and executing IP strategies, advising and assisting in company creation and building and maintaining stakeholder relations.
Ian Bell
Head, Licensing and Business Development
Ian Bell
Head, Licensing and Business Development
With a background in molecular biology, Ian is an experienced business developer. He has spent 20 years in academic technology transfer at the University of Calgary and University of British Columbia, Canadian provincial and federal governments, industry and as an independent consultant.
At Oncode Ian uses his extensive expertise to assess and commercialize life science inventions such as novel therapeutics, antibodies, diagnostics and molecular biology tools; develop IP protection strategies; market and negotiate valorization agreements; create companies and build and maintain academic-industry and stakeholder relations.
View Bio
Ian Bell
Head, Licensing and Business Development
With a background in molecular biology, Ian is an experienced business developer. He has spent 20 years in academic technology transfer at the University of Calgary and University of British Columbia, Canadian provincial and federal governments, industry and as an independent consultant.
At Oncode Ian uses his extensive expertise to assess and commercialize life science inventions such as novel therapeutics, antibodies, diagnostics and molecular biology tools; develop IP protection strategies; market and negotiate valorization agreements; create companies and build and maintain academic-industry and stakeholder relations.